Physician profile
Robert S Scheinberg
NPI 1144252388
$9,946.24
in general payments reported to CMS, 2019-2025
40 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 85% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $180 · 2021: $1,224 · 2022: $975 · 2023: $1,921 · 2024: $2,490 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,108 · Travel and Lodging: $840 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,108.40 |
| Travel and Lodging | $839.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,646.26 | 2019-2025 | Rinvoq, Skyrizi |
| Stryker Corporation | $839.88 | 2024 | Salvation |
| Genzyme Corporation | $688.23 | 2019-2025 | |
| Incyte Corporation | $631.37 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $616.75 | 2019-2025 | Tremfya |
| Janssen Biotech, INC. | $613.47 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $456.68 | 2019-2025 | Sotyktu |
| Ucb, INC. | $411.45 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $401.90 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $387.82 | 2023-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $358.08 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $345.42 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $321.90 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $307.55 | 2019-2025 | Libtayo, Dupixent |
| Dermavant Sciences, INC. | $214.51 | 2023-2024 | Vtama |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scheinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.